摘要:
This present disclosure is related to the field of 5-fluoro-2-oxopyrimidine-1-(2H)-carboxylates and their derivatives and to the use of these compounds as fungicides.
摘要:
The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
摘要:
Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.
摘要:
A compound is provided having formula (I) wherein R?1 and R2¿ independently denote a methylene, ethylene or unbranched or branched C¿3-16? alkylene, alkenylene or alkynylene group which is unsubstituted or substituted with one or more halogen, hydroxyl or amine groups, wherein in the unbranched or branched C3-16 alkylene, alkenylene or alkynylene group an internal alkylene carbon atom in the carbon backbone thereof can be replaced by an oxygen atom, R?3 and R4¿ (i) independently denote (a) hydrogen, (b) a methyl, ethyl, vinyl or unbranched or branched C¿3-16? alkyl, alkenyl or alkynyl group which is unsubstituted or substituted with one or more halogen, hydroxyl or amine groups, wherein in said unbranched or branched C3-16 alkyl, alkenyl or alkynyl group an internal alkylene carbon atom in the carbon backbone thereof can be replaced by an oxygen atom, (c) a cycloalkyl, alkylcycloalkyl, alkynylcycloalkyl or alkynylcycloalkyl group having 5 to 16 carbon atoms which is unsubstituted or substituted with one or more halogen, hydroxyl or amine groups, or (d) an aryl, alkaryl, aralkyl, alkenylaryl, aralkenyl, alkynylaryl or aralkynyl group having 6 to 16 carbon atoms which is unsubstituted or substituted with one or more halogen, hydroxyl or amine groups, or (ii) jointly with the nitrogen atom form a cyclic or aromatic amine which is unsubstituted or substituted with one or more alkyl, alkenyl, alkynyl, halogen, hydroxyl or amine groups, X denotes O, S, -NH- or -NR?5¿-, and R5 denotes methyl, ethyl, or unbranched or branched C¿3-16? alkyl, or a pharmaceutically acceptable salt thereof, wherein t he compound is in equilibrium at physiological pH with a protonated form thereof. Methods of making the compounds, compositions including the compounds and methods of treatment of conditions involving reactive oxygen species are also provided.
摘要:
This present disclosure is related to the field of N1-acyl-5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.
摘要:
Disclosed is a polymer material obtained by having at least one polymer selected from the group consisting of acrylic acid polymers, polyester polymers and polycarbonate polymers contain a compound represented by the following general formula (2). (In the formula, A21 and A22 represent an atom other than a hydrogen atom or a carbon atom; Y21 and Y22 independently represent a hydrogen atom or a monovalent substituent, provided that at least one of Y21 and Y22 represents a substituent having a Hammett substituent constant σp of not less than 0.2, or alternatively Y21 and Y22 may combine together to form a ring; and (B) represents an atomic group necessary for forming a five-membered or six-membered ring together with A21, A22 and a carbon atom.)
摘要:
The invention provides a method for reducing esophageal irritation associated with alpha-lipoic acid upon oral administration through the use of the trometamol salt of alpha-lipoic acid. The present invention also provides for the increased solubility of alpha-lipoic acid through the use of the trometamol salt of alpha-lipoic acid. The trometamol salt of alpha-lipoic acid, as provided by the present invention can be used as a substitute for regular, non-salt forms alpha-lipoic acid in dietary supplement compositions.